# Pharmacogenetics of SGLT2 Inhibitors

> **NCT02462421** · PHASE4 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 30 (actual)

## Conditions studied

- Diabetes Mellitus
- Gout
- Hyperuricemia

## Interventions

- **DRUG:** Canagliflozin

## Key facts

- **NCT ID:** NCT02462421
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Did not meet recruitment targets.
- **Last updated:** 2022-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02462421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02462421, "Pharmacogenetics of SGLT2 Inhibitors". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02462421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*